Table 1. Clinical profile and ARV treatment history for study participants and positive controls.
| Participant | HIA | IIA | LIA | POS1 | POS2 |
| Elisa at Time Point #1 (TP1) | + | + | + | + | + |
| Western Blot TP1 | + | + | + | + | + |
| PBMC TP1 | 12/9/2004 | 5/5/2004 | 11/9/2004 | 3/8/2007 | 8/10/2006 |
| GALT TP1 | 12/13/2004 | 5/6/2004 | 11/9/2004 | N/A | N/A |
| Estimated Duration of Infection PBMC TP1 | 68 days | 30 days | 88 days | 78 days | 54 days |
| Fiebig Stage TP1 | VI | V | VI | V | V |
| CD4 Count cells/ul TP1 | 442 | 250 | 489 | 656 | 560 |
| Plasma HIV-1 RNA (VL) copies/ml TP1 | 148,000 | 5,560,000 | 86,100 | 46,700 | 72,300 |
| cART Start Date | 12/16/2004 | 5/6/2004 | 11/16/2004 | N/A | N/A |
| Initial cART regimen | TDF/FTC+EFV | TDF/FTC+LPV/r | TDF/FTC+EFV | N/A | N/A |
| Time to 1st VL <50 copies/ml | 110 days | 113 days | 119 days | N/A | N/A |
| Time to PBMC TP2 | 1.3 y (489 d) | 1.1 y (414 d) | 1.4 y (506 d) | 1.9 y (691 d) | 1.8 y (670 d) |
| Time to GALT TP2 | 1.3 y (489 d) | 2.1 y (761 d) | 1.3 y (483 d) | N/A | N/A |
| CD4 Count cells/µl TP2 | 774 | 629 at PBMC TP2 | 556 | 486 | 684 |
| 903 at GALT TP2 | |||||
| Plasma VL copies/ml TP2 | <20 | <20 at PBMC TP2 | <20 | 27,300 | >100,000 |
| <50 at GALT TP2 |